Iterum Therapeutics to Present Data at IDWeek 2021
28. September 2021 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
08. September 2021 08:55 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
13. August 2021 07:00 ET
|
Iterum Therapeutics plc
--Type A meeting with FDA expected late Q3 to define pathway to potential approval for Oral Sulopenem following July’s Complete Response Letter-- --Cash Runway into Second Half of 2023-- --Company...
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results on August 13, 2021
06. August 2021 07:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Oral Sulopenem
26. Juli 2021 07:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, July 26, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Provides Regulatory Update
01. Juli 2021 18:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, July 01, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Provides Update on NDA Review
27. Mai 2021 17:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, May 27, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports First Quarter 2021 Financial Results
14. Mai 2021 07:00 ET
|
Iterum Therapeutics plc
FDA Review of NDA for Oral Sulopenem Continues; Current Prescription Drug User Fee Act (PDUFA) date of July 25, 2021 Cash Runway into First Half of 2023 Company to host conference call today at...
Iterum Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on May 14, 2021
07. Mai 2021 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, May 07, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral...
Iterum Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
06. April 2021 08:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, April 06, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...